HLB Pharmaceutical KRX:047920KOSDAQ
HLB제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked40since Sep 11
In Q2 2026, HLB Pharmaceutical reported revenue of ₩62.3bn, up 32.7% year on year, and an operating loss of ₩31m. HLB Pharmaceutical (HLB제약) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Revenue +30% Asset deal Share pledge Screener
HLB Pharmaceutical quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩62.3bn | +32.7% | −₩31m margin −0.0% | −₩57m |
| Q1 2026 | ₩65.7bn | +89.5% | ₩1.0bn margin 1.6% | ₩720m |
| Q4 2025 derived | ₩63.4bn | +91.7% | ₩835m margin 1.3% | ₩2.3bn |
| Q3 2025 | ₩60.6bn | +74.3% | ₩34m margin 0.1% | −₩161m |
| Q2 2025 | ₩46.9bn | +31.2% | −₩1.8bn margin −3.8% | ₩910m |
| Q1 2025 | ₩34.6bn | +3.6% | ₩2.0bn margin 5.7% | ₩1.6bn |
| Q4 2024 derived | ₩33.1bn | -1.9% | −₩1.2bn margin −3.7% | ₩2.2bn |
| Q3 2024 | ₩34.8bn | +0.4% | ₩855m margin 2.5% | ₩948m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
HLB Pharmaceutical top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest HLB Pharmaceutical news Korean headlines
-
HLB제약, 향남 GMP공장에 550억원 투자
1 more on this story · 1 outlets
- HLB제약 "향남 GMP공장 개선에 550억원 투자"뉴시스경제 · Oct 1 18:01
-
아리바이오 합병 철회에 홀딩스 급락…HLB제약 이틀 새 63%↑[바이오맥짚기]
1 more on this story · 1 outlets
- 아리바이오 합병 철회에 홀딩스 급락…HLB제약 이틀 새 63%↑[바이오맥짚기]이데일리 · Oct 1 06:41